FABCLEAN

Financial & Operational Performance - H1 FY27 consolidated revenue grew 75% YoY to ₹133.23 Cr; EBITDA grew 75% to ₹10.28 Cr with EBITDA margin at 7.67%; PAT grew 55% to ₹5.15 Cr. - Order book stood at ₹468 Cr (Consolidated ₹517 Cr) as of Sept 30, 2026, comprising Pharma & Life Sciences (₹217 Cr), Renewables (₹195 Cr), and Data Centers/Semiconductors (₹56 Cr). Management Guidance & Outlook - Guided for full-year revenue growth of 70% to 80% with equivalent growth in margins, upgrading earlier conservative targets of 20-30%. - H2 margins and profitability expected to be materially higher than H1, aiming for full-year PAT margins around 7-8%. - Aiming to reach 25-30% cleanroom market share in India and become the top integrated player by 2030. Working Capital & Cash Flow - Trade receivables stood at ₹129 Cr as of September 30 due to reference project terms, with ₹23 Cr recovered in October; cash flows expected to turn positive by next financial year. - Debt remains modest at ₹40 Cr against a net worth of ₹112 Cr (debt-to-equity ratio at 0.37x). Growth Drivers & Capex - Operationalized Hyderabad facility adding 50,000 sq meters capacity with automated lines. - Benefiting from structural industry tailwinds such as revised Schedule M norms in Pharma, Semiconductor Mission fabs, and cooling requirements in AI data centers.

- Audio & Video recording link submitted for the Earnings Conference Call held on November 4, 2026. - The concall discussed the Unaudited Financial Results for the half-year ended September 30, 2026. - Access link provided on the company's website.

- H1 FY27 Consolidated Revenue rose 75% YoY to ₹133.23 Cr compared to ₹76.19 Cr in H1 FY26. - EBITDA grew 75% YoY to ₹10.28 Cr with a 7.67% margin. - PAT surged 55% YoY to ₹5.15 Cr. - Order book expanded 2.35x to ₹468 Cr with a ₹600 Cr hot pipeline.

- H1 FY27 Consolidated Revenue from Operations grew 74.88% YoY to ₹133.23 Cr; PAT increased 54.65% YoY to ₹5.15 Cr. - Order book expanded to ~₹470 Cr from ₹199 Cr in March 2026, with a ₹600 Cr hot pipeline. - Management expects stronger H2 FY27 profitability supported by volume execution and operating leverage.

H1 FY27 Standalone Revenue ₹107.06Cr vs ₹49.53Cr (▲116% YoY) EBITDA ₹6.70Cr vs ₹3.20Cr (▲110% YoY) PAT ₹4.50Cr vs ₹2.93Cr (▲54% YoY) EBITDA Margin 6.26% vs 6.46% (▼20bps)

H1 FY27 Standalone Revenue ₹107.06Cr vs ₹49.53Cr (▲116% YoY) EBITDA ₹6.70Cr vs ₹3.20Cr (▲109% YoY) PAT ₹4.50Cr vs ₹2.93Cr (▲54% YoY) EBITDA Margin 6.26% vs 6.46% (▼20bps)

H1 FY27 Standalone Revenue ₹107.06Cr vs ₹49.53Cr (▲116% YoY) EBITDA ₹6.70Cr vs ₹3.20Cr (▲110% YoY) PAT ₹4.50Cr vs ₹2.93Cr (▲54% YoY) EBITDA Margin 6.26% vs 6.46% (▼20bps) - The proposal for raising funds through preferential allotment on a private placement basis has been deferred.

- Board meeting scheduled on Friday, October 30, 2026. - To consider and approve standalone and consolidated unaudited financial results for the half year ended September 30, 2026. - To consider a proposal for raising funds via preferential allotment of equity shares or convertible warrants.

Order Win: Fabtech Cleanrooms Ltd secured consolidated orders worth ₹35.60 crore in September 2026 across Pharma, Data Centres, Semiconductors, and other sectors Order Book: Consolidated order book stands at ₹468.18 crore as of 30 September 2026 Pipeline: Orders under active consideration total ₹394.55 crore

- Fabtech Cleanrooms Limited held its Annual General Meeting (AGM) on September 28, 2026. - All 6 resolutions set out in the AGM notice were passed unanimously with 100% votes in favour based on remote e-voting and voting at the meeting. - Key approvals included the adoption of audited standalone and consolidated financial statements for FY2026 and the re-appointment of Mr. Amjad Adam Arbani as Director. - Shareholders also approved material related party transactions with Fabtech Technologies Limited and Kelvin Air Conditioning and Ventilation Systems Private Limited.

- Fabtech Cleanrooms Limited held its 11th Annual General Meeting (AGM) on September 28, 2026, through Video Conferencing. - Mr. Shyam Nagorao Khante chaired the meeting as the regular Chairman was unable to attend. - Shareholders considered and discussed financial statements, re-appointment of director, material related party transactions, and ratification of the name change certificate.

- Trading window closed from October 01, 2026 for Designated Persons and immediate relatives. - Closure remains until 48 hours after announcement of H1 FY27 financial results. - Board meeting date for approval of results will be intimated in due course.